This funding augments the previously announced $15 million Series D financing.
AxioMed’s Freedom Lumbar Disc is currently on the market in the EU and advancing toward completion of its Investigational Device Exemption pivotal study in the U.S. AxioMed intends to follow a similar regulatory and marketing pathway as the FLD with its Freedom Cervical Disc, which recently received a CE Mark for introduction in the EU.
Related Articles on Spine Devices:
20 Spine Devices Receive FDA 510(k) Clearance in May
Korean FDA Approves Mazor Robotics’ Renaissance Robotic Platform
Crocker Spinal Technologies to Develop BYU Spine Device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
